Product Description
Belnacasan prevents the activation of a particular enzyme, Caspase-1, which plays a major role in activating this damaging immune response brought on by COVID-19. The goal of this medication being a more targeted treatment that aims to prevent the devastating immune response. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05164120)
Mechanisms of Action: CAAP Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Vertex
Company Location: BOSTON MA 02210
Company CEO: Reshma Kewalramani
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Epilepsies, Partial|Psoriasis|Epilepsy|COVID-19
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| MedStar-COVID-19-belnacasan | P2 |
Completed |
COVID-19 |
2022-07-18 |
|
| 2011-004156-19 | P2 |
Completed |
Epilepsy |
2013-09-24 |
|
| VX11-765-402 | P2 |
Terminated |
Epilepsies, Partial |
2013-08-01 |
31% |
| VX09-765-401 | P2 |
Completed |
Epilepsies, Partial |
2010-11-01 |